Business Wire

NATIONAL-TSING-HUA

7.12.2022 10:01:34 CET | Business Wire | Press release

Share
Opening Ceremony Held for NTHU’s Center for Dissection Education and Research

The opening ceremony for National Tsing Hua University (NTHU) in Taiwan’s Center for Dissection Education and Research, which cost over NT$100 million, was recently held. The ceremony included a memorial service for the cadaver donors. As an expression of gratitude, the first batch of students in the Post-baccalaureate Program in Medicine also offered Chinese bellflowers to the donors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005054/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Students of the Post-baccalaureate Program in Medicine at NTHU offering Chinese bellflowers to those who have donated their cadavers to the program. (Photo: National Tsing Hua University)

At the ceremony, former NTHU president Hocheng Hong signed the first donation agreement, which indicates that the donor has unconditionally pledged his body for education and research after death, for the purposes of advancing medical science.

Current NTHU president W. John Kao thanked Hocheng for his contributions to medical education at NTHU, including raising NT$2 billion, which has enabled NTHU to set up state-of-the-art anatomy classrooms. In addition, NTHU has also appointed three full-time and two part-time faculty in human anatomy---the foundation of medical education.

On behalf of NTHU, Kao sincerely thanked all those who donated their cadavers, as well as their family members for agreeing with their loved ones’ intentions to benefit medical education. Kao said that cadavers are essential for medical education, and that they help students to acquire the knowledge necessary for treating countless patients in their future medical careers.

Each of the students of the Post-baccalaureate Program in Medicine offered a Chinese bellflower to the donors Zhou Zhen-yu and Liu Gui-zhen, and together sang the song “Grateful Heart” to express their deepest gratitude. In the words of student representative Shen Ho-chien, “The end of your life is the starting point of our medical education. Thus, we begin our studies by thanking you with utmost humility and respect.”

Hocheng said that life is like a boat sailing on water, and there will come a day when the boat returns to shore; at that time, instead of simply abandoning the boat, some generous souls choose to pass it on for others to use. He also noted that he is especially grateful for all the medical professionals who have helped him in so many ways, and happy to have had the opportunity to support medical education.

Hocheng observed that the grueling process of establishing the medical program is finally bearing fruit, now that the first batch of medical students has enrolled and work on the NTHU Hospital is underway in Taoyuan. He also said that he is pleased to sign the donation agreement, and sees it as an expression of his unreserved support for medical education at NTHU.

One of the program’s faculty members is Chen Shih-chieh, who has 28 years of experience teaching gross anatomy. He said that the spacious, state-of-the-art facilities at the newly completed Center for Dissection Education and Research provide an optimal learning environment, free of any formalin odor. The dissection lab and the cadaver room maintain negative pressure throughout the day, and are equipped with air conditioning and a real-time system for monitoring formaldehyde concentrations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005054/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye